Variable 18F-fluorodeoxyglucose uptake in gastric cancer is associated with different levels of GLUT-1 expression

Nuclear Medicine Communications

Volumn 31, Issue 6, 2010, Pages 532-538

  Alakus, Hakan ^a   Batur, Mert ^a   Schmidt, Matthias ^a   Drebber, Uta ^a   Baldus, Stephan E ^b   Vallböhmer, Daniel ^a   Prenzel, Klaus L ^a   Metzger, Ralf ^a   Bollschweiler, Elfriede ^a   Hölscher, Arnulf H ^a   Monig, Stefan P ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

Gastric cancer; GLUT 1; Immunohistochemistry; Positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE TRANSPORTER 1;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER GRADING; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PROTEIN EXPRESSION; SIGNET RING CARCINOMA; STOMACH CARCINOMA; WORLD HEALTH ORGANIZATION;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL TRANSPORT; FEMALE; FLUORODEOXYGLUCOSE F18; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCOSE TRANSPORTER TYPE 1; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; STOMACH NEOPLASMS;

EID: 77951759262     PISSN: 01433636     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNM.0b013e32833823ac     Document Type: Article

References (36)

1. Kwee RM, Kwee TC. Imaging in local staging of gastric cancer: a systematic review. J Clin Oncol 2007; 25:2107-2116.
2. Siewert JR, Bö ttcher K, Stein HJ, Roder JD. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg 1998; 228:449-461.
3. Hansson LE, Sparén P, Nyrén O. Survival in stomach cancer is improving: results of a nationwide population-based Swedish study. Ann Surg 1999; 230:162-169.
4. Kim JP, Kwon OJ, Oh ST, Yang HK. Results of surgery on 6589 gastric cancer patients and immunochemosurgery as the best treatment of advanced gastric cancer. Ann Surg 1992; 216:269-278.
5. Bollschweiler E, Breckheimer S, Mö nig SP, Hö lscher AH. The prognostic relevance of age and comorbidity in patients with resected gastric cancer. Zentralbl Chir 2009; 134:71-76.
6. Brennan MF. Current status of surgery for gastric cancer: a review. Gastric Cancer 2005; 8:64-70.
7. Fleming ID, Cooper JS, Henson DE, Henson DE, Hutter RVP, Kennedy BJ, et al. Manual for staging of cancer. American Joint Committee on Cancer (AJCC). 5th ed. Philadelphia: Lippincott; 1997.
8. Menges M. Diagnosis, staging and therapy of gastric cancer. Z Gastroenterol 2004; 42:767-773.
9. Chen J, Cheong JH, Yun MJ, Kim J, Lim JS, Hyung WJ, et al. Improvement in preoperative staging of gastric adenocarcinoma with positron emission tomography. Cancer 2005; 103:2383-2390.
10. Mö nig SP, Zirbes TK, Schrö der W, Baldus SE, Lindemann DG, Dienes HP, et al. Staging of gastric cancer: correlation of lymph node size and metastatic infiltration. AJR Am J Roentgenol 1999; 173:365-367.
11. Gretschel S, Moesta KT, Hü nerbein M, Lange T, Gebauer B, Stroszczinski C, et al. New concepts of staging in gastrointestinal tumors as a basis of diagnosis and multimodal therapy. Onkologie 2004; 27:23-30.
12. Mukai K, Ishida Y, Okajima K, Isozaki H, Morimoto T, Nishiyama S. Usefulness of preoperative FDG-PET for detection of gastric cancer. Gastric Cancer 2006; 9:192-196.
13. Isselbacher KJ. Sugar and amino acid transport by cells in culture - differences between normal and malignant cells. N Engl J Med 1972; 286:929-933.
14. Yonekura Y, Benua RS, Brill AB, Som P, Yeh SD, Kemeny NE, et al. Increased accumulation of 2-deoxy-2-[18F]fluoro-D-glucose in liver metastases from colon carcinoma. J Nucl Med 1982; 23:1133-1137.
15. Minn H, Joensuu H, Ahonen A, Klemi P. Fluorodeoxyglucose imaging: a method to assess the proliferative activity of human cancer in vivo. Comparison with DNA flow cytometry in head and neck tumors. Cancer 1988; 61:1776-1781.
16. Holm E, Hagmü ller E, Staedt U, Schlickeiser G, Gü nther HJ, Leweling H, et al. Substrate balances across colonic carcinomas in humans. Cancer Res 1995; 55:1373-1378.
17. Tschmelitsch J, Weiser MR, Karpeh MS. Modern staging in gastric cancer. Surg Oncol 2000; 9:23-30.
18. Stahl A, Ott K, Weber WA, Becker K, Link T, Siewert JR, et al. FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings. Eur J Nucl Med Mol Imaging 2003; 30:288-295.
19. Berger KL, Nicholson SA, Dehdashti F, Siegel BA. FDG PET evaluation of mucinous neoplasms: correlation of FDG uptake with histopathologic features. AJR Am J Roentgenol 2000; 174:1005-1008.
20. De Potter T, Flamen P, Van Cutsem E, Penninckx F, Filez L, Bormans G, et al. Whole-body PET with FDG for the diagnosis of recurrent gastric cancer. Eur J Nucl Med Mol Imaging 2002; 29:525-529.
21. Kawamura T, Kusakabe T, Sugino T, Watanabe K, Fukuda T, Nashimoto A, et al. Expression of glucose transporter-1 in human gastric carcinoma: association with tumor aggressiveness, metastasis, and patient survival. Cancer 2001; 92:634-641.
22. Montel-Hagen A, Kinet S, Manel N, Mongellaz C, Prohaska R, Battini JL, et al. Erythrocyte Glut1 triggers dehydroascorbic acid uptake in mammals unable to synthesize vitamin C. Cell 2008; 132:1039-1048.
23. Schmidt M, Bollschweiler E, Dietlein M, Mö nig SP, Kobe C, Vallbö hmer D, et al. Mean and maximum standardized uptake values in [(18)F]FDG-PET for assessment of histopathological response in oesophageal squamous cell carcinoma or adenocarcinoma after radiochemotherapy. Eur J Nucl Med Mol Imaging 2009; 36:735-744.
24. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma-2nd english edition. Gastric Cancer 1998; 1:10-24.
25. Wittekind C, Compton CC, Greene FL, Sobin LH. TNM residual tumor classification revisited. Cancer 2002; 94:2511-2516.
26. Stokkel MP, Ten Broek FW, Hordijk GJ, Koole R, Van Rijk PP. Preoperative evaluation of patients with primary head and neck cancer using dual-head 18fluorodeoxyglucose positron emission tomography. Ann Surg 2000; 231:229-234.
27. Pieterman RM, Van Putten JW, Meuzelaar JJ, Mooyaart EL, Vaalburg W, Koë ter GH, et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med 2000; 343:254-261.
28. Flamen P. Positron emission tomography in colorectal cancer. Best Pract Res Clin Gastroenterol 2002; 16:237-251.
29. Flamen P, Lerut A, Van Cutsem E, De Wever W, Peeters M, Stroobants S, et al. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol 2000; 18:3202-3210.
30. Ott K, Weber WA, Lordick F, Becker K, Busch R, Herrmann K, et al. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol 2006; 24:4692-4698.
31. Mochiki E, Kuwano H, Katoh H, Asao T, Oriuchi N, Endo K. Evaluation of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography for gastric cancer. World J Surg 2004; 28:247-253.
32. Yamada A, Oguchi K, Fukushima M, Imai Y, Kadoya M. Evaluation of 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in gastric carcinoma: relation to histological subtypes, depth of tumor invasion, and glucose transporter-1 expression. Ann Nucl Med 2006; 20:597-604.
33. Macheda ML, Rogers S, Best JD. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol 2005; 202:654-662.
34. Mueckler M, Caruso C, Baldwin SA, Panico M, Blench I, Morris HR, et al. Sequence and structure of a human glucose transporter. Science 1985; 229:941-945.
35. Kim WS, Kim YY, Jang SJ, Kimm K, Jung MH. Glucose transporter 1 (GLUT1) expression is associated with intestinal type of gastric carcinoma. J Korean Med Sci 2000; 15:420-424.
36. Wahl RL, Beanlands RSB. Principles and practice of PET and PET/CT. Philadelphia: Lippincott Williams & Wilkins; 2009. pp. 119-121.